NEW YORK, April 10, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals,
Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY),
Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE:
ESC). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
--
Puma Biotechnology, Inc. Analyst Notes
On April 7, 2014, Puma
Biotechnology, Inc. (Puma Biotechnology) presented positive results
from the Phase II clinical trial of its investigational drug PB272
(neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2
TRIAL) in an oral presentation at the American Association for
Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. According to Puma
Biotechnology, the I-SPY 2 TRIAL (Investigation of Serial Studies
to Predict Your Therapeutic Response with Imaging And moLecular
Analysis 2) is a collaborative effort among academic investigators
from approximately 20 major cancer research centers across the
country, the U.S. Food and Drug Administration, Quantum Leap
Healthcare Collaborative, and the Foundation for the National
Institutes of Health (FNIH) Cancer Biomarkers Consortium including
major supporters such as The Safeway Foundation and the Bill Bowes
Foundation. The full analyst notes on Puma Biotechnology, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04102014/PBYI/report.pdf
--
Alnylam Pharmaceuticals, Inc. Analyst Notes
On April 7, 2014, Alnylam
Pharmaceuticals, Inc. (Alnylam) announced that the European Patent
Office (EPO) has upheld the McSwiggen EP 1423406 ('406) patent in
oral opposition proceedings in Munich,
Germany. According to the release, the McSwiggen patent
estate is owned by Alnylam, and was recently obtained through the
Company's acquisition of Sirna Therapeutics from Merck.
Additionally, the Company stated that the McSwiggen patent family
comprises a core component of Alnylam's overall intellectual
property (IP) estate for the advancement of RNAi therapeutics as a
new class of medicines. Commenting on the news, Laurence Reid, Ph.D., Senior Vice President and
Chief Business Officer of Alnylam, stated, "We are pleased with the
European Patent Office's decision to uphold the '406 patent from
our McSwiggen patent family, a key component of the IP estate we
recently obtained through our acquisition of Sirna Therapeutics
from Merck. This patent has broad and significant claims describing
chemical modifications of RNAi therapeutics, which we believe are
critical for the development and commercialization of all RNAi
therapeutics. Our IP estate remains a cornerstone in our efforts to
advance RNAi therapeutics to patients in need." The full analyst
notes on Alnylam Pharmaceuticals, Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/04102014/ALNY/report.pdf
--
INSYS Therapeutics, Inc. Analyst Notes
On March 31, 2014, INSYS
Therapeutics, Inc. (INSYS) announced that it has completed its
previously disclosed three-for-two stock split, effected through a
stock dividend. According to the release, the record date for the
stock split was the close of business on March 17, 2014, and share distribution occurred
on March 28, 2014. Additionally,
INSYS said that consequent to the dividend, shareholders received
one additional share of the Company common stock, par value
$0.0002145, for each two shares they
held as of the record date. INSYS President and CEO, Michael L. Babich, stated, "This action
increases the liquidity of our stock, and reflects our confidence
in the strength and continuing growth of our Company. We are
committed to remaining profitable and continuing to build
shareholder value with our marketed products and through our robust
R&D pipeline." The full analyst notes on INSYS Therapeutics,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04102014/INSY/report.pdf
--
Peregrine Pharmaceuticals Inc. Analyst Notes
On April 7, 2014, Peregrine
Pharmaceuticals Inc.'s (Peregrine Pharmaceuticals) stock went up by
2.72% to $1.89 per share. For the
past three-month trading period, the Company's stock went up by
19.62%, compared to the Nasdaq Composite which went down by 1.77%.
The full analyst notes on Peregrine Pharmaceuticals Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04102014/PPHM/report.pdf
--
VIVUS Inc. Analyst Notes
On April 7, 2014, VIVUS Inc.'s
(VIVUS) stock went down 6.09%, at $5.09 per share. Over the past five-day trading
period, VIVUS shares went down by 11.00%, compared to the Nasdaq
Composite which went down by 2.83% over the same trading session.
The full analyst notes on VIVUS Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/04102014/ESC/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review